ASX Briefs...everything...in three bullet points

OSTEOPORE LIMITED (ASX: OSX)

Osteopore and CellHeal signed a binding term sheet to collaborate on commercializing Osteopore's regenerative implant technology in China, Hong Kong, Macau, and Taiwan.
The partnership will focus on two core projects: stem cells for dental applications and tendon and cartilage regeneration, with CellHeal covering its own costs estimated at AUD$4 million.
Upon obtaining necessary regulatory approvals, Osteopore's technology will be commercialized and introduced into the Chinese market through CellHeal's distribution and pharmaceutical networks.

2023-06-08 08:54:00

Osteopore's bioresorbable mesh product, Osteomesh®, has received reimbursement approval from Discovery Health Medical Scheme (DHMS), South Africa's most prominent medical scheme.
Osteomesh® is a semi-flexible bioresorbable mesh that supports bone tissue regeneration and is made from polycaprolactone (PCL), which slowly resorbs into the body over 18-24 months.
South Africa's private healthcare sector accounts for around half of the country's health expenditure, with approximately 200 private hospitals and over 500 craniomaxillofacial surgeons.

2023-05-16 08:19:00

Osteopore successfully transitions to new EU Medical Device Regulation (MDR), joining a select group of companies (only 12.7% of certificates transitioned by the end of 2022).
Company now positioned to further penetrate the European market worth USD 550 million annually.
Osteopore's two main products have a market opportunity of around USD 410 million annually.

2023-04-27 08:30:00

Osteopore announces a strategic sub-distribution partnership with Kelyniam through its U.S. sales distribution partner, Bioplate Inc., to further penetrate the cranial implant market.
Kelyniam specializes in custom prosthetics production and will focus on securing sales in approximately 20 hospitals across 8 states, including prestigious institutions like Johns Hopkins Hospital and Boston Medical Center.
Osteopore products have FDA clearance and are available in the U.S., with the partnership expected to enhance market penetration and contribute to future growth.

2023-04-11 08:24:00

Osteopore acquires multiple medical distribution businesses, anticipating boosted revenue in the aesthetic rhinoplasty product line.
The acquisition is expected to provide higher margins, improved efficiency, and shared resources through vertical integration and direct retail sales control.
Company aims to leverage new resources for competitive advantage, improved offerings, and enhanced customer satisfaction, targeting sales growth beyond pre-pandemic levels.

2023-03-31 09:37:00

Osteopore has acquired multiple medical distribution businesses that accounted for 40%-45% of their total sales.
The acquisition will enable them to become vertically integrated, and control the entire process from manufacturing to direct retail sales.
By selling direct they expect to achieve greater revenue and increased margins.

2023-01-23 08:24:00